Authors : Pooja Kumari; Kunwar Aditi; Dr. Ayesha Fatima

Volume/Issue : Volume 11 - 2026, Issue 1 - January

Google Scholar : https://tinyurl.com/53wjv5fu

Scribd : https://tinyurl.com/3vfv9v76

DOI : https://doi.org/10.38124/ijisrt/26jan1562

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Methicillin resistant Staphylococcus aureus (MRSA) is a non motile bacterium that frequently colonizes the nose and skin without causing disease. When it enters the body through breaches like cuts or invasive procedures, it can disseminate, causing a wide range of infections, from skin and soft tissue infections (painful nodules, abscesses) to life threatening conditions like pneumonia and endocarditis. Both healthcare associated (HA-MRSA) and community associated (CA-MRSA) strains contribute significantly to a rising global disease burden. Diagnosis of MRSA is achieved through culture and sensitivity testing, Gram staining, quantitative PCR, and antibiotic susceptibility assays. The organism employs multiple resistance mechanisms, including biofilm formation, efflux pumps, and modification of antibiotic targets, a challenge increasingly evident during recent global health crises. The clinical presentation is often characterized by painful erythematous nodules and purulent lesions, frequently accompanied by fever. Severe cases can rapidly progress to necrotizing soft tissue disease. Standard first line therapy relies on agents like vancomycin and daptomycin, with alternatives including linezolid and ceftaroline. However, resistance and drug toxicity complicate management. To combat these issues, novel therapeutic strategies are being developed, including newer antibiotics (e.g., tigecycline, tedizolid), optimized delivery systems (e.g., inhalable vancomycin nanoparticles), and bacteriophage therapy. Core prevention measures meticulous hand hygiene, environmental cleaning, and targeted decolonization remain essential to limit transmission. The increasing prevalence and expanding resistance mechanisms of MRSA underscore the critical need for continued research and robust infection control in the 21st century.

Keywords : MRSA, Antimicrobial Resistance (AMR), Biofilm Formation, Tigecycline, Bacteriophage Therapy, Vancomycin, Antimicrobial Resistance, AMR, Efflux Pumps, Cephalosporins.

References :

1. 'Methicillin  -  resistant Staphylococcus aureus', Wikipedia, The Free Encyclopaedia. Retrieved from   en.wikipedia.org/wiki/Methicillin  -  resistant_Staphylococcus_aureus
2. Wang N, Li W, et al. Laurocapram, a transdermal enhancer, boosts cephalosporin’s antibacterial activity against methicillin  -  resistant Staphylococcus aureus. Biochemical pharmacology. 2024 Sep; 227(116404): ISSN 0006  -  2952,   doi.org/10.1016/j.bcp.2024.116404.
3. 3. Peyrani P, Ramirez J. What is the best therapeutic approach to methicillin  -  resistant Staphylococcus aureus pneumonia? Curr Opin Infect Dis. 2015;28(2):164  -  170. doi:10.1097/QCO.0000000000000149   pubmed.ncbi.nlm.nih.gov/25692268/
4. Vanamala K, Tatiparti K, Bhise K, et al. Novel approaches for the treatment of methicillin  -  resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discov Today. 2021;26(1):31  -  43. doi:10.1016/j.drudis.2020.10.011
5. Ian M. Gould. MRSA bacteraemia. International Journal of Antimicrobial Agents. Volume 30, Supplement 1. Nov 2007; Pages 66  -  70, ISSN 0924  -  8579,  doi.org/10.1016/j.ijantimicag.2007.06.023.
6. Craft KM, Nguyen JM, Berg LJ, Townsend SD. Methicillin  -  resistant Staphylococcus aureus (MRSA): antibiotic  -  resistance and the biofilm phenotype. Medchemcomm. 2019;10(8):1231  -  1241. Published 2019 Mar 14. doi:10.1039/c9md00044e
7. Kaushik A, Kest H, Sood M, Steussy BW, Thieman C, Gupta S. Biofilm Producing Methicillin  -  Resistant Staphylococcus aureus (MRSA) Infections in Humans: Clinical Implications and Management. Pathogens. 2024;13(1):76. Published 2024 Jan 15. doi:10.3390/pathogens13010076
8. Pecoraro C. Synthesis And Biological Evaluation Of Novel Small Molecules As Promising Alternative Agents To Counteract Drug Resistance In Cancer And Microbial Infections. 2022. 343
9. Michalik M, Podbielska  -  Kubera A, Et.al. A. Antibiotic Resistance of Staphylococcus aureus Strains  -  Searching for New Antimicrobial Agents  -  Review. Pharmaceuticals (Basel). 2025;18(1):81. Published 2025 Jan 11. P. 1  -  2. doi:10.3390/ph18010081
10. Vestergaard M, Frees D, et.al. Antibiotic Resistance and the MRSA Problem. Microbiol Spectr. 2019;7(2):10.1128/microbiolspec.gpp3  -  0057  -  2018. doi:10.1128/microbiolspec.GPP3  -  0057  -  2018
11. Munita JM, Et.al . Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4(2):10.1128 /microbiolspec.VMBF  -  0016  -  2015.doi:10.1128/microbiolspec.VMBF  -  0016  -  2015
12. Gould IM, et al. New insights into methicillin  -  resistant Staphylococcus aureus. International Journal of Antimicrobial Agents. 2012;39(4):283  -  91. doi:10.1016/j.ijantimicag.2011.11.019.
13. Gould IM. Treatment of methicillin  -  resistant Staphylococcus aureus (MRSA) to vancomycin  -  resistant S. aureus (VRSA). International Journal of Antimicrobial Agents. 2013 Jun;42 Supplement 1: S17  -  21.   doi.org/10.1016/j.ijantimicag.2013.04.006
14. Chen HH, Hon PY, Hsu LY. Ceftaroline  -    -  An Anti  -  MRSA Cephalosporin and Its Implications for Singapore. Ann Acad Med Singap. 2014;43(3):177  -  186.
15. Galfo, Valentina et al. Therapeutic drug monitoring of antibiotics for methicillin  -  resistant Staphylococcus aureus infections: an updated narrative review for clinicians. Clinical Microbiology and Infection. 2025 Feb;31(2):194 – 200
16. Molina KC, Morrisette T, Miller MA, Huang V, Fish DN. The Emerging Role of β  -  Lactams in the Treatment of Methicillin  -  Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2020;64(7):e00468  -  20. Published 2020 Jun 23. doi:10.1128/AAC.00468  -  20
17. Arshad, S., Hartman, P., & Zervos, M. J. (2014). A novel treatment option for MRSA pneumonia: ceftaroline fosamil  -  yielding new hope in the fight against a persistent infection. Expert Review of Anti  -  Infective Therapy, 12(7), 727–729. doi.org/10.1586/14787210.2014.908118
18. Holubar M, Meng L, Alegria W, Deresinski S. Bacteremia due to methicillin  -  resistant Staphylococcus aureus: an update on new therapeutic approaches. Infectious Disease Clinics of  North America. 2020 Dec;34(4):849  -  861. doi:10.1016/j.idc.2020.04.003.
19. Poon H, Chang MH, Fung HB. Ceftaroline fosamil: a cephalosporin with activity against methicillin  -  resistant Staphylococcus aureus. Clinical Therapeutics. 2012 Apr;34(4):743  -  765. doi.org/10.1016/j.clinthera.2012.02.025.
20. Abdelaziz MM, Hefnawy A, Anter A, Abdellatif MM, Khalil MAF, Khalil IA. Inhalable vancomycin  -  loaded lactose microparticles for treatment of MRSA pneumonia. Journal of Drug Delivery Science and Technology. 2023 Feb;80:104150. doi.org/10.1016/j.jddst.2023.104150
21. Ledger EVK, Recker M, Massey RC. Expression of mecA increases daptomycin tolerance in Staphylococcus aureus. mBio. 2025 Sep 22:e0225025. doi: 10.1128/mbio.02250  -  25
22. Shaaban F, Salem Sokhn E, Khalil C, Saleh FA. Antimicrobial activity of adipose  -  derived mesenchymal stromal cell secretome against methicillin  -  resistant Staphylococcus aureus. Stem Cell Res Ther. 2025;16(1):21. Published 2025 Jan 23. doi:10.1186/s13287  -  025  -  04138  -  3
23. Koumaki D, Maraki S, Evangelou G, Koumaki V, Gregoriou S, Kouloumvakou S, Susceptibility of Staphylococcus aureus  -  Infected Dermatoses. Journal of Clinical Medicine. 2025; 14(4):1084. doi.org/10.3390/jcm14041084
24. Barua N, Chan BCL, Lau CB, Leung PC, Fung KP, Ip M. Antivirulence Properties of Kuraridin Against Methicillin  -  Resistant Staphylococcus aureus (MRSA). Biomedicines. 2025;13(3):564. Published 2025 Feb 24. doi:10.3390/biomedicines13030564
25. Makled AF, Labeeb AZ, Badr EAE, et al. Myrtenol's Effectiveness against Hospital  -  Acquired Methicillin  -  Resistant Staphylococcus aureus: Targeting Antibiofilm and Antivirulence Properties. Int J Microbiol. 2024;2024:8832448. Published 2024 Oct 16. doi:10.1155/2024/8832448
26. Shao K, Yang Y, Gong X, Chen K, Liao Z, Ojha SC. Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions. Infect Drug Resist. 2025;18:1007  -  1033. Published 2025 Feb 19. doi:10.2147/IDR.S510024
27. Jameson, Fauci, Kasper, Hauser, Longo, Loscalzo. Staphylococcal Infections: Microbiology and taxonomy. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editor, Harrison’s principles of internal medicine, 20th edition vol.2. New York: McGraw  -  Hill Education; 2018. P.1071  -  1072.
28. Surinder Kumar. Staphylococcus: Cultural characteristics, biochemical reactions, and laboratory diagnosis. In: Surinder Kumar, editor, Textbook of Microbiology, 1st edition. New Delhi: Jaypee; 2012. P.230  -  235.
29. Cornelissen CN, Fisher BD, Harvey RA. Staphylococci: General features, laboratory identification. In: Harvey RA, editor, Microbiology, 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2013. P. 69  -  74.
30. Gherardi G. Staphylococcus aureus Infection: Pathogenesis and Antimicrobial Resistance. International Journal of Molecular Sciences. 2023; 24(9):8182 doi.org/10.3390/ijms24098182
31. Methicillin  -  resistant Staphylococcus aureus (MRSA) Basics. (2025). Methicillin  -  resistant Staphylococcus aureus (MRSA) Basics   -   US Centers for disease control and prevention. Retrieved from   www.cdc.gov/mrsa/about/index.html.
32. Nicholas M Brown, Anna L Goodman, Carolyne Horner, Abi Jenkins, Erwin M Brown, Treatment of methicillin  -  resistant Staphylococcus aureus (MRSA): updated guidelines from the UK, JAC  -  Antimicrobial Resistance, Volume 3, Issue 1, March 2021.
33. Zhang L, Zhang Y, Tian L, Shen Q, Ma X. Doxifluridine effectively kills antibiotic  -  resistant Staphylococcus aureus in chronic obstructive pulmonary disease. Microbiol Spectr. Published online November 12, 2024. doi:10.1128/spectrum.01805  -  24
34. Shao K, Yang Y, Gong X, Chen K, Liao Z, Ojha SC. Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions. Infect Drug Resist. 2025 Feb 19;18:1007  -  1033. Doi: 10.2147/IDR.S510024.
35. Northwestern Medicine. Symptoms of Skin and Soft Tissue Infections (Including MRSA) [Internet]. Northwestern Medicine; ©2025. Available from:   www.nm.org/conditions  -  and  -  care  -  areas/infectious  -  disease/skin  -  and  -  soft  -  tissue  -  infections/symptoms.
36. What Does MRSA Look Like?. Mark D. Fisher. John Hopkins Medicine. Retrieved from   www.hopkinsmedicine.org/health/conditions  -  and  -  diseases/what  -  does  -  mrsa  -  look  -  like
37. Yok  -  Ai Que and Philippe Moreillon. Section  -   F Bacterial Diseases chapter  -  128 Staphylococcus aureus  (Including Staphylococcal   Toxic Shock Syndrome). Therapy. In: John E.Bennett, Raphel Dolin ,Martin J Blaser, editor, Infectious Disease Essentials 1st edition. Philadelphia (PA): Elsevier; 2017.
38. Silva V, Almeida L, Gaio V, et al. Biofilm Formation of Multidrug  -  Resistant MRSA Strains Isolated from Different Types of Human Infections. Pathogens. 2021;10(8):970. Published 2021 Jul 30. doi:10.3390/pathogens10080970
39. Biofilm Formation of Multidrug  -  Resistant MRSA Strains Isolated from Different Types of Human Infections   -   PMC
40. Patel S, Preuss CV, Bernice F. Vancomycin. [Updated 2024 Oct 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK459263/
41. Vancomycin   -   StatPearls   -   NCBI Bookshelf
42. Peter J Stogios , Alexei Savchenko. Molecular mechanisms of vancomycin resistance. Protein Sci. 2020 Jan 23;29(3):654–669. Doi: 10.1002/pro.3819
43. KD Tripathi. Essentials of Medical Pharmacology.8th edition. Jaypee Brothers Medical Publishers (P) Ltd.2019.Section 12: Antimicrobial Drugs , chapter  -  55.Macrolide,Lincosamide,Glycopeptide and other Antibacterial Antibiotics; Urinary Antiseptics. Glycopeptide antibiotics (Vancomycin ) p.806
44. Trevor M. Speight and Nicholas H.G. Chapter  -  31 Infectious diseases {Bacterial and fungal), Chapter  -  24 Renal diseases: Glycopeptides, Vancomycin. In: Trevor M. Speight and Nicholas H.G, 4th edition vol.2.New delhi: John wiley and sons Ltd; 2011.
45. Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119  -  120. doi:10.1186/cc1871.
46. Reynolds B. Vancomycin mechanism of action | resistance and more [Internet]. DoseMeRx; [cited 2025 Nov 14]. Available from:   doseme  -  rx.com/vancomycin/articles/vancomycin  -  mechanisms  -  of  -  action#Resistance
47. Patel S, Saw S. Daptomycin. StatPearls. 2025 Jan.    www.ncbi.nlm.nih.gov/books/NBK470407/
48. Judith N. Steenbergen, Jeff Alder, Grace M. Thorne, Francis P. Tally. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram  -  positive infections. Journal of Antimicrobial Chemotherapy. 2005 Mar;55(3):283–288.   doi.org/10.1093/jac/dkh546
49. Vancomycin Hydrochloride for Injection (U.S. FDA prescribing information). [Internet]. U.S. Food & Drug Administration; c2018 [cited 2025 Nov 14]. Available from:   www.accessdata.fda.gov/drugsatfda_docs/label/2018/209481s000lbl.pdf FDA Access Data
50. Glenn W. Kaatz, Tammy S. Lundstrom, Susan M. Seo. Mechanisms of daptomycin resistance in Staphylococcus aureus. International Journal of Antimicrobial Agents. 2006;28(4): 280  -  287.   doi.org/10.1016/j.ijantimicag.2006.05.030.
51. Mechanisms of daptomycin resistance in Staphylococcus aureus   -   ScienceDirect
52. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 446598, Clindamycin. Retrieved November 13, 2025 from    pubchem.ncbi.nlm.nih.gov/compound/Clindamycin.
53. Murphy PB, Bistas KG, Patel P, et al. Clindamycin. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK519574/
54. Vestergaard M.Frees D.Ingmer H. 2019. Antibiotic Resistance and the MRSA Problem. Microbiol Spectr. 2019 Mar 22;7(2)    doi.org/10.1128/microbiolspec.gpp3  -  0057  -  2018    Antibiotic Resistance and the MRSA Problem | Microbiology Spectrum
55. E. Bouza, P. Muñoz. Linezolid: pharmacokinetic characteristics and clinical studies. Clinical Microbiology and Infection. 2001;7(4):75  -  82.   doi.org/10.1046/j.1469  -  0691.2001.00061.x.   www.sciencedirect.com/science/article/pii/S1198743X1530118X
56. Azzouz A, Preuss CV. Linezolid. [Updated 2024 Mar 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK539793/
57. Cadena JNair S, HenaoMartinez AF, Jorgensen JH, Patterson JE, Sreeramoju PV 2011.  Dose of Trimethoprim  -  Sulfamethoxazole To Treat Skin and Skin Structure Infections Caused by Methicillin  -  Resistant Staphylococcus aureus . Antimicrob Agents Chemother 55:  doi.org/10.1128/aac.00706  -  11
58. Courtney Zeigler, PharmD, BCPS. Sulfamethoxazole/Trimethopri­m (Bactrim, Septra, others) Uses, Side Effects, and More. www.webmd.com/drugs/2/drug  -  5530/bactrim  -  ds  -  oral/details
59. Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim  -  Sulfamethoxazole Revisited. Arch Intern Med. 2003;163(4):402–410. Doi:10.1001/archinte.163.4.402
60. Kemnic TR, Coleman M. Trimethoprim Sulfamethoxazole. [Updated 2022 Nov 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK513232/
61. Hae Won Shin1,2, Jinsook Lim1, Semi Kim1, Jimyung Kim1, Gye Cheol Kwon1, and Sun Hoe Koo. Characterization of Trimethoprim  -  Sulfamethoxazole Resistance Genes and Their Relatedness to Class 1 Integron and Insertion Sequence Common Region in Gram  -  Negative Bacilli. JMB
62. J. Microbiol. Biotechnol. (2015), 25(1), 137–142 http://dx.doi.org/10.4014/jmb.1409.09041
63. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 135398735, Rifampicin. Retrieved November 5, 2025 from   pubchem.ncbi.nlm.nih.gov/compound/Rifampicin.
64. Alex Poppen, PharmD. Rifampin (Rifadin, Rimactane­) – Uses, Side Effects, and More www.webmd.com/drugs/2/drug  -  1744/rifampin  -  oral/details
65. Beloor Suresh A, Rosani A, Patel P, et al. Rifampin. [Updated 2023 Nov 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK557488/
66. Jansen van Rensburg, M.J., Whitelaw, A.C. & Elisha, B.G. Genetic basis of rifampicin resistance in methicillin  -  resistant Staphylococcus aureus suggests clonal expansion in hospitals in Cape Town, South Africa. BMC Microbiol 12, 46 (2012). doi.org/10.1186/1471  -  2180  -  12  -  46
67. Lamb, H.M., Figgitt, D.P. & Faulds, D. Quinupristin/Dalfopristin. Drugs 58, 1061–1097 (1999).   doi.org/10.2165/00003495  -  199958060  -  00008
68. Gurk  -  Turner C. Quinupristin/dalfopristin: the first available macrolide  -  lincosamide  -  streptogramin antibiotic. Proc (Bayl Univ Med Cent). 2000 Jan;13(1):83  -  6. Doi: 10.1080/08998280.2000.11927646.
69. David E. Kleiner, Chapter 12 – Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins, Editor(s): Alastair Burt, MacSween’s  Pathology of the Liver (Eighth Edition),Elsevier,2024,Pages 726  -  841, doi.org/10.1016/B978  -  0  -  7020  -  8228  -  3.00012  -  0 Henry Poon, Mei H. Chang, Horatio B. Fung. Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin  -  Resistant Staphylococcus Aureus, Clinical Therapeutics. 2012; 34(4):743  -  765,ISSN 0149  -  2918,   doi.org/10.1016/j.clinthera.2012.02.025.
70. Bavaro, D. F., Belati, A., Bussini, L., Cento, V., Diella, L., Gatti, M., … Bartoletti, M. (2023). Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin  -  resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future. Expert Opinion on Drug Safety, 23(1), 9–36. doi.org/10.1080/14740338.2023.2299377
71. Bui T, Patel P, Preuss CV. Cephalosporins. [Updated 2024 Feb 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK551517/
72. Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent). 2006 Apr;19(2):155  -  61. Doi:10.1080/08998280.2006.11928154.
73. Shutter MC, Akhondi H. Tetracycline. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan  -  . Available from:   www.ncbi.nlm.nih.gov/books/NBK549905/
74. Definition of doxifluridine – NCI Drug Dictionary – NCI.   www.cancer.gov/publications/dictionaries/cancer  -  drug/def/doxifluridine.
75. Zhang L, Zhang Y, Tian L, Shen Q, Ma X.2024.Doxifluridine effectively kills antibiotic  -  resistant Staphylococcus aureus in chronic obstructive pulmonary disease. Microbiol Spectr12:e01805  -  24.  doi.org/10.1128/spectrum.01805  -  24.
76. Barua, N., Chan, B. C. L., Lau, C. B.  -  S., Leung, P.  -  C., Fung, K. P., & Ip, M. (2025). Antivirulence Properties of Kuraridin Against Methicillin  -  Resistant Staphylococcus aureus (MRSA). Biomedicines, 13(3), 564.   doi.org/10.3390/biomedicines13030564
77. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 135398735, Rifampicin. Retrieved November 5, 2025 from pubchem.ncbi.nlm.nih.gov/compound/Rifampicin